The Dow industrials closed at a record high on Thursday, boosted by gains in Wal-Mart, but the S&P 500 was little changed as energy shares tracked crude futures prices lower.
Overall retail sales, which account for about one-third of consumer spending, climbed 0.3 percent in October, topping expectations for a 0.2 percent increase.
Other data showed U.S. import prices fell in September by the most in more than two years as the cost of petroleum products declined and a strong dollar made it cheaper for Americans to buy goods from abroad.
"The fall in gasoline prices is absolutely what the doctor ordered and I would be surprised if the holiday season wasn't better than expected as a result of that," said John De Clue, chief investment officer at U.S. Bank Wealth Management in Minneapolis, Minnesota.
While the Dow and S&P have continued to set record highs, recent gains have been modest, with the S&P 500 yet to post a gain of at least 1 percent this month.
"This is a market that has something for everyone but there are still a lot of people on the sidelines that are skeptical," said De Clue.
The Dow Jones industrial average fell 6.94 points, or 0.04 percent, to 17,645.85, the S&P 500 gained 0.05 points, or 0 percent, to 2,039.38 and the Nasdaq Composite dropped 5.21 points, or 0.11 percent, to 4,674.93.
The Thomson Reuters/University of Michigan preliminary November reading on consumer sentiment is expected later in the session at 9:55 a.m. (1355 GMT.) Expectations call for a reading of 87.5 versus the final October reading of 86.9.
The S&P 500 is up 0.4 percent for the week and has rallied 9.5 percent from a six-month low in October, buoyed by supportive economic data and corporate earnings. For the year so far, it is up 10.3 percent.
Baker Hughes gained 4.1 percent to $61.13. The oilfield services company said it was in preliminary merger talks with its larger rival Halliburton Co, which was up 4 percent to $55.94. The two stocks were the best performers on the S&P 500.
Geron Corp surged 33.3 percent to $3.08 after it licensed its cancer compound to a Johnson & Johnson unit for up to $935 million.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)